Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data

Simona Duranti; Antonella Pietragalla; Gennaro Daniele; Camilla Nero; Francesca Ciccarone; Giovanni Scambia; Domenica Lorusso

doi:10.3390/cancers13092089

Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data

Simona Duranti, Antonella Pietragalla, Gennaro Daniele, Camilla Nero, Francesca Ciccarone, Giovanni Scambia, Domenica Lorusso

Research output: Contribution to journal › Review article › peer-review

Abstract

Human papillomavirus (HPV) infection is the recognized cause of almost all cervical cancers. Despite the reduction in incidence due to a wide use of screening programs and a specific vaccine, the prognosis of cervical cancer remains poor, especially for late‐stage and relapsed disease. Considering the elevated rates of PD‐L1 expression in up to 80% of cervical cancers, a strong rationale supports the use of immunotherapy to restore the immune response against tumor. The aim of this review is to analyze the possible role of immune checkpoint inhibitors in cervical cancer treatment, with a particular focus on the rationale and on the results of phase I and II clinical trials. An overview of ongoing phase III studies with possible future areas of development is also provided.

Original language	English
Article number	2089
Journal	Cancers
Volume	13
Issue number	9
DOIs	https://doi.org/10.3390/cancers13092089
Publication status	Published - May 1 2021

Keywords

Cervical cancer
CTLA4
Immune checkpoint inhibitors
Immunotherapy
PD‐1
PD‐L1

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers13092089

Cite this

@article{68eb49b708bd46228b649a5b0782926b,

title = "Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data",

abstract = "Human papillomavirus (HPV) infection is the recognized cause of almost all cervical cancers. Despite the reduction in incidence due to a wide use of screening programs and a specific vaccine, the prognosis of cervical cancer remains poor, especially for late‐stage and relapsed disease. Considering the elevated rates of PD‐L1 expression in up to 80% of cervical cancers, a strong rationale supports the use of immunotherapy to restore the immune response against tumor. The aim of this review is to analyze the possible role of immune checkpoint inhibitors in cervical cancer treatment, with a particular focus on the rationale and on the results of phase I and II clinical trials. An overview of ongoing phase III studies with possible future areas of development is also provided.",

keywords = "Cervical cancer, CTLA4, Immune checkpoint inhibitors, Immunotherapy, PD‐1, PD‐L1",

author = "Simona Duranti and Antonella Pietragalla and Gennaro Daniele and Camilla Nero and Francesca Ciccarone and Giovanni Scambia and Domenica Lorusso",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = may,

day = "1",

doi = "10.3390/cancers13092089",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI AG",

number = "9",

}

TY - JOUR

T1 - Role of immune checkpoint inhibitors in cervical cancer

T2 - From preclinical to clinical data

AU - Duranti, Simona

AU - Pietragalla, Antonella

AU - Daniele, Gennaro

AU - Nero, Camilla

AU - Ciccarone, Francesca

AU - Scambia, Giovanni

AU - Lorusso, Domenica

PY - 2021/5/1

Y1 - 2021/5/1

N2 - Human papillomavirus (HPV) infection is the recognized cause of almost all cervical cancers. Despite the reduction in incidence due to a wide use of screening programs and a specific vaccine, the prognosis of cervical cancer remains poor, especially for late‐stage and relapsed disease. Considering the elevated rates of PD‐L1 expression in up to 80% of cervical cancers, a strong rationale supports the use of immunotherapy to restore the immune response against tumor. The aim of this review is to analyze the possible role of immune checkpoint inhibitors in cervical cancer treatment, with a particular focus on the rationale and on the results of phase I and II clinical trials. An overview of ongoing phase III studies with possible future areas of development is also provided.

AB - Human papillomavirus (HPV) infection is the recognized cause of almost all cervical cancers. Despite the reduction in incidence due to a wide use of screening programs and a specific vaccine, the prognosis of cervical cancer remains poor, especially for late‐stage and relapsed disease. Considering the elevated rates of PD‐L1 expression in up to 80% of cervical cancers, a strong rationale supports the use of immunotherapy to restore the immune response against tumor. The aim of this review is to analyze the possible role of immune checkpoint inhibitors in cervical cancer treatment, with a particular focus on the rationale and on the results of phase I and II clinical trials. An overview of ongoing phase III studies with possible future areas of development is also provided.

KW - Cervical cancer

KW - CTLA4

KW - Immune checkpoint inhibitors

KW - Immunotherapy

KW - PD‐1

KW - PD‐L1

UR - http://www.scopus.com/inward/record.url?scp=85104646909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104646909&partnerID=8YFLogxK

U2 - 10.3390/cancers13092089

DO - 10.3390/cancers13092089

M3 - Review article

AN - SCOPUS:85104646909

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 9

M1 - 2089

ER -

Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this